AGA presents cutting-edge research and new learning opportunities at DDW® 2013
May 17, 2013Orlando, FL (May 17, 2013) -- Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week® (DDW) 2013, the largest and most prestigious gastroenterology meeting, from May 18 to 21, 2013, at the Orange County Convention Center in Orlando, FL. DDW is jointly sponsored by the American Gastroenterological Association (AGA) Institute, the American Association for the Study of Liver Diseases (AASLD), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT).
AGA researchers will present exciting, cutting-edge data during the meeting that will help change the way physicians diagnose and treat gastrointestinal (GI) disorders. All data presented during DDW is embargoed until the beginning of the presentation or an official DDW press conference, whichever occurs first. A list of press activities is available at http://www.ddw.org/press. Newsroom staff can facilitate interviews with researchers presenting at the sessions highlighted below.
All sessions will be held in the Orange County Convention Center. For more information on presentations and data being presented, visit http://www.myddw.org.
Late-Breaking Abstract Sessions
Three late breaking abstract sessions will highlight hot new data accepted for presentation at DDW:
- Liver clinical science late-breaking abstracts: May 21, 8 a.m., Room 207
- Basic science late-breaking abstracts: May 21, 10 a.m., in Room 205B
- General GI clinical science late-breaking abstracts: May 21, 10 a.m., Room 303ABC
New Data on the Gut Microbiome
As part of AGA's strategic focus on the gut microbiome, AGA offers speaker sessions and oral research abstracts at DDW 2013. Sessions will discuss the myriad of possibilities that the gut microbiome offers to GI basic and translational researchers, clinicians and patients. New research will report on the microbiome's impact on IBD, cirrhosis, celiac disease, colon cancer and more. View the complete list of invited speaker sessions and oral research abstracts on the gut microbiome -- http://www.gastro.org/Microbiome_presentations_DDW2013.pdf.
Plenary Sessions
New for 2013, DDW will feature a joint AGA-ASGE Presidential Plenary Session on May 18 at 10 a.m. ET in Room 415 -- Valencia.
From 8 a.m. to 10 a.m., the AGA-ASGE joint plenary session will highlight innovative clinical research on IBD, pancreatic cancer, colorectal cancer and gastroparesis, among other topics.
From 10 a.m. to noon, AGA Institute President, Loren A. Laine, MD, AGAF, and his ASGE counterpart have invited noted experts to present on hot topics in gastroenterology and GI endoscopy. Presentations include:
- "Should Colonoscopy Be the Test of Choice for CRC Screening: Yes," Douglas K. Rex, MD, AGAF, FASGE, Indiana University School of Medicine; University Hospital in Indianapolis
- "Should Colonoscopy Be the Test of Choice for CRC Screening: No," David A. Lieberman, MD, AGAF, Oregon Health Sciences University
- "Applying Genetics in Clinical Practice: Screening and Management of Colorectal Cancer," John M. Carethers, MD, AGAF, University of Michigan
- "Gut Microbiome: Implications for Clinical Practice," Gail A. Hecht, MD, MS, AGAF, University of Illinois College of Medicine
- "Hepatitis C: What Therapy This Month?" Michael W. Fried, MD, University of North Carolina at Chapel Hill
- Inactivation of a Single Allele of P120catenin Dramatically Accelerates KRAS-Driven Carcinogenesis in the Pancreas (2:03 p.m. ET, Abstract #436a). Maximilian Reichert et al.
- Complete Conversion of Crypt Progenitor Cells Into ATOH1-Positive Cells by Targeted Deletion of DLL1 and Dll4 in LGR5-Positive Intestinal Stem Cells (2:15 p.m. ET, Abstract #436b). Hiromichi Shimizu et al.
- Tissue-Specific Knockout of the RNA-Binding Protein HuR Inhibits Intestinal Mucosal Growth by Down-Regulating Wnt Signaling (2:27 p.m. ET, Abstract #436c). Lan Liu et al.
- A Novel In Vitro SPEM Culture Provides a Model for Characterization of Metaplasia in the Stomach (2:39 p.m. ET, Abstract #436d). Victoria G. Weis et al.
- Crohn's Disease-Associated Adherent-Invasive Escherichia coli Suppress Autophagy Response to Replicate Intracellularly by Regulating Host MicroRNA Expression (3:21 p.m. ET, Abstract #436e). Hang T. Nguyen et al.
- Human Gut Microbiota Modulates Gut Serotonergic Pathway and Motility (3:33 p.m. ET, Abstract #436f). Purna C. Kashyap et al.
AGA has developed special sessions to meet the unique needs of physicians who are new to the field. Participants will learn about all aspects of starting a career in clinical practice or research, have the opportunity to network with mentors and peers, and review board material. All sessions occur on Monday, May 20, and include:
- Board Review Session (8 a.m., Room 208) -- designed around content from the new Digestive Diseases Self-Education Program® 7, this session will serve as a primer for third-year fellows preparing for the board exam, as well as a review course for others wanting to test their knowledge.
- Career and Professional Related Issues (12:30 p.m., Room 208) -- will provide advice on common career issues such as choosing a practice type and location, developing an attractive CV, interviewing, negotiating contracts, and work-life balance.
- Maximizing Opportunities within Fellowship Training: Advice from Fellows and Faculty (2 p.m., Room 313) -- presents information on how to create a niche within GI. A designated portion of the session will also examine GI career opportunities in research, hepatology and education, as well as provide an assessment of advanced clinical training opportunities.
AGA presents a committee-sponsored symposium, AGA Academy of Educators: Planning for Promotion: Promoting Your Professional Portfolio (May 21, 8 a.m., Room 202AB), for academic clinicians or medical educators who are interested in taking their careers to the next level. This interactive session will highlight important topics in portfolio preparation and will teach attendees how to create a CV worthy of promotion. Presentations will be followed by roundtable discussions led by faculty leaders.
AGA Institute-Rome Foundation Lectureship
During the sixth annual AGA Institute-Rome Foundation Lectureship (May 19, 8 a.m., Room 109A), experts will provide a comprehensive overview of GI permeability in gastroenterology and its clinical significance to functional GI disorders.
-end-
About the American Gastroenterological Association The American Gastroenterological (AGA) Association is the trusted voice of the GI community. Founded in 1897, the American Gastroenterological Association has grown to include close to 17,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. Learn more at http://www.gastro.org.
Follow us on Twitter @AmerGastroAssn. Become an AGA fan on Facebook.
About DDW
DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18 - 21, 2013, at the Orange County Convention Center, Orlando, FL. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit http://www.ddw.org.
Follow us on Twitter @DDWMeeting; hashtag #DDW13. Become a DDW fan on Facebook.
American Gastroenterological Association
Related Colorectal Cancer Articles from Brightsurf:
Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.
A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.
Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.
Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.
Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.
Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.
Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.
A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.
Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.
Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.
Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.
A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.
Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.
Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.
Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.
Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.
Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.
A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.
Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.
Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.
Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.